Norethindrone acetate versus dienogest for pain relief in endometriosis related pain: A randomized controlled trial

Gurbuz TB, Tansu Bahar Gürbüz, Tansu Bahar Gurbuz, Kiper Aslan, Işıl Kasapoğlu, Kasapoglu I, Isil Kasapoglu, Ludovico Muzii, Muzii L, Gürkan Uncu, Gurkan Uncu, Uncu G
European journal of obstetrics, gynecology, and reproductive biology · 2025 · vol. 310 , pp. 113940 · doi:10.1016/j.ejogrb.2025.113940 · PMID:40233572 · W4408992589
RCT OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-09 ⓘ

This randomized trial found norethindrone acetate and dienogest equally effective for endometriosis pain relief, though NETA showed greater endometrioma size reduction and a lower dropout rate.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: To determine which progestin, norethindrone acetate (NETA) or dienogest, is more effective in alleviating pain associated with endometriosis? STUDY DESIGN: This single-center, prospective, randomized trial included 70 patients aged 18-40 years attending the Endometriosis Clinic (April 2022-April 2023). Participants were randomly assigned to receive either NETA (5 mg daily) or dienogest (2 mg daily). Pain levels were assessed using a visual analog scale (VAS) at baseline and at 6- and 12-month follow-ups. Discontinuation rates, dropout reasons, and side effects were also recorded. RESULTS: The study included 70 patients, with 40 randomized to the dienogest group and 30 to the NETA group. Both groups showed significant reductions in pain scores at all follow-ups, with no significant differences between them. At baseline, dysmenorrhea scores were 7.43 ± 2.9 (NETA) and 7.23 ± 2.87 (dienogest). By 12 months, both groups had a dysmenorrhea score of 0.00 ± 0.00. Chronic pelvic pain scores improved to 1.06 ± 2.43 (NETA) and 0.00 ± 0.00 (dienogest) (p = 0.058). NETA demonstrated a significantly greater reduction in endometrioma size (p = 0.037). At the sixth month, there were 23 patients in the NETA group and 21 patients in the dienogest group, while 16 patients in the NETA group and 18 patients in the dienogest group completed the treatment. Side effect profiles were comparable; however, the dropout rate at six months was higher in the dienogest group (47.5 % vs. 23.3 %; p = 0.026). CONCLUSIONS: Both progestins effectively reduced pain scores, but NETA achieved a greater reduction in endometrioma size and had a lower dropout rate, potentially due to its higher dose. These findings suggest NETA 5 mg/day may be a better approach instead of dienogest for the endometriosis treatment. TRIAL REGISTRATION NUMBER: International Clinical Trials Registry Platform No. NCT05476172.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosischronic_pelvic_pain

MeSH descriptors

Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (16)

Cited by (5)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-15T06:05:17.309911+00:00
License: CC0 · commercial use OK